Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium

Abstract:
ULURU Inc. (NYSE Amex: ULU) announced today that the Company will have a commercial exhibit and present scientific data at the Symposium on Advances in Skin and Wound Care and Wound Healing Society ("SAWC/WHS") which will be held on April 14 - 17, 2011 in Dallas, TX.

ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium

Addison, TX | Posted on April 15th, 2011

The 24th Annual SAWC/WHS meeting is considered the premier educational wound care program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists and researchers are expected to attend the meeting.

In addition to having a commercial exhibit, ULURU will present seven scientific posters at the meeting. There are four clinical posters demonstrating the clinical advantages of Altrazeal® and three scientific posters which outline the science behind Altrazeal® which provides the unique properties that result in numerous clinical benefits.

Of the four clinical posters being presented, one poster titled, "Preliminary Evaluation on the Application of a Powder Dressing in the Fixation and Treatment of Chronic Wounds Resulting from Trauma with Epidermal Separation," authored by Dr. Scott Gorenstein, M.D., Clinical Director, Wound Healing Center and Hyperbaric Medicine Winthrop-University Hospital, is important as it further expands Altrazeal®'s clinical data on the treatment of geriatric trauma wounds. Of the patients reporting pre-treatment pain, this symptom was immediately resolved upon application of Altrazeal®. The median time to heal these difficult to treat wounds was 14 days. These healing times are significantly shorter than those times previously experienced at this facility.

Commenting on the clinical results, Dr. Scott Gorenstein stated, "Since I started using Altrazeal® in the treatment of these difficult to heal and often painful geriatric wounds, I have experienced significantly improved healing rates. I look forward to conducting a controlled clinical study to demonstrate the clinical advantages of Altrazeal® in the treatment of geriatric wounds and to provide the data to establish Altrazeal® as the standard of care in this patient population."

The scientific posters demonstrate the unique properties of Altrazeal®; including controlled release of actives and the ability to affect biofilm formation. In wound care treatment, biofilms are considered a major impediment to healing. The poster titled, "Modification of Nanoparticle Aggregate Surfaces to Affect Bacterial Migration and Biofilm Formation," authored by Dr. John St. John, Ph.D., Vice President of ULURU Inc., demonstrates the ability to control biofilm formation. The data shows that it is possible to reduce biofilm formation by changing particle sizes and the materials used to produce dressings. Also, the data demonstrates that the material composition of Altrazeal® and the size of the nanoparticles in the formulation have been optimized to reduce biofilm formation.

Commenting on the poster presentation Dr. John St. John stated, "In the clinical setting physicians have often commented that biofilm formation in contaminated wounds is minimized when the wounds are treated with Altrazeal®, which contributes to the improved clinical outcomes they are experiencing. The data presented on this poster looks at the underlying mechanism for biofilm inhibition beneath Altrazeal®. Further, the data demonstrates clearly, for the bacteria types studied, by adjusting ULURU's patent Nanoflex® formulation parameters and materials biofilm formation can significantly reduce biofilm formation. The poster shows it is possible to build a biofilm-inhibiting wound dressing where the inhibition is a result of physical interactions at the nanoscale level rather than using a bactericidal agent."

The exhibition booth at SAWC/WHS provides an opportunity for the Company to cost effectively present Altrazeal® to an extensive audience of wound care professionals. Clinical data, product information and demonstration of the application techniques of Altrazeal® will be provided by our sales representatives.

Commenting on participation at the conference, Kerry P. Gray, President and CEO stated, "Expanding the clinical data and scientific support for Altrazeal® is a key component of our marketing strategy. The poster presentations provide us with important data that further confirms the clinical advantages of Altrazeal® in the geriatric trauma market. The biofilm data expands the scientific base supporting Altrazeal® and further differentiates us from any of the competition. We expect that this additional data will generate significant interest in Altrazeal® and greater product usage."

Further information on the Spring 2011 SAWC Conference is available at spring.sawc.net.

####

About ULURU Inc.
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the clinical benefits of Altrazeal®, and anticipated significant additional interest in Altrazeal®. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

For more information, please click here

Contacts:
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Switching to spintronics: Berkeley Lab reports on electric field switching of ferromagnetism at room temp December 17th, 2014

ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Nanomedicine

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Nanomedicine expert joins Rice faculty: Gang Bao combines genetic, nano and imaging techniques to fight disease December 17th, 2014

Announcements

Switching to spintronics: Berkeley Lab reports on electric field switching of ferromagnetism at room temp December 17th, 2014

ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Military

UCLA engineers first to detect and measure individual DNA molecules using smartphone microscope December 15th, 2014

Nanoshaping method points to future manufacturing technology December 11th, 2014

Stacking two-dimensional materials may lower cost of semiconductor devices December 11th, 2014

Industrial Nanotech, Inc. Expands Government and Defense Projects December 10th, 2014

Events/Classes

Bruker Introduces BioScope Resolve High-Resolution BioAFM System: Featuring PeakForce Tapping for Quantitative Bio-Mechanical Property Mapping December 16th, 2014

TCL Launches World’s Most Advanced TV in the World’s Largest Market: New Quantum Dot TVs with Color IQ™ Optics Deliver OLED-Quality Color at a Fraction of the Price December 15th, 2014

Stanford team combines logic, memory to build a 'high-rise' chip: Today circuit cards are laid out like single-story towns; Futuristic architecture builds layers of logic and memory into skyscraper chips that would be smaller, faster, cheaper -- and taller December 15th, 2014

PETA science consortium to present at Society for Risk Analysis meeting December 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE